(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Tuesday, October 28, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

A Predictive Model Combining Clinical and Laboratory Parameters to Predict Anti-tnf Response in Patients with Psoriatic Arthritis
Abstract Poster Presenter: Raquel Granados, MD – Hospital Universitario Reina Sofia
10:30 AM - 12:30 PM Central Time

Association Between Skin and Joint Symptom Control and Patient-reported Pain and Health Status Among Patients with Psoriatic Arthritis in the Corevitas Psoriatic Arthritis/spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drugs
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
10:30 AM - 12:30 PM Central Time

Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
10:30 AM - 12:30 PM Central Time

Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
Abstract Poster Presenter: Saakshi Khattri, MD, MBBS – Mount Sinai Medical Center
10:30 AM - 12:30 PM Central Time

Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
10:30 AM - 12:30 PM Central Time

Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Abstract Poster Presenter: Fabian Proft, MD – Charité Universityhospital Berlin
10:30 AM - 12:30 PM Central Time

Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
Abstract Poster Presenter: Dafna Gladman, MD, FRCPC, FACR, MACR – University of Toronto, Toronto Western Hospital
10:30 AM - 12:30 PM Central Time

ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
Abstract Poster Presenter: José Miguel Sequí-Sabater, Jr, MD,MSc (he/him/his) – La Ribera University Hospital, Rheumatology Department
10:30 AM - 12:30 PM Central Time

Classification of "Difficult-to-Manage Axial Spondyloarthritis": A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Abstract Poster Presenter: Gözde Kart Bayram, MD – Hacettepe University
10:30 AM - 12:30 PM Central Time

Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
10:30 AM - 12:30 PM Central Time

Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
Abstract Poster Presenter: MARIA KONSTA, MD, PhD (she/her/hers) – Sismanoglion Hospital, Athens, Greece
10:30 AM - 12:30 PM Central Time

Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Abstract Poster Presenter: Punith Chirumamilla, MD (he/him/his) – Baptist Memorial Hospital North Mississippi
10:30 AM - 12:30 PM Central Time

Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Abstract Poster Presenter: Rocio Gonzalez Molina, PhD – Hospital Reina Sofía
10:30 AM - 12:30 PM Central Time

Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Abstract Poster Presenter: Francesco Fulvio Bizzarri, MD – Complejo Hospitalario de Jaen
10:30 AM - 12:30 PM Central Time

Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial
Abstract Poster Presenter: Xiaofei Shi, MD – The First Affiliated Hospital of Henan University of Science and Technology
10:30 AM - 12:30 PM Central Time

Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Abstract Poster Presenter: Xu Jian, PhD – First Affiliated Hospital of Kunming Medical University
10:30 AM - 12:30 PM Central Time

Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Abstract Poster Presenter: Cristina Valero, MD – Hospital de la Princesa
10:30 AM - 12:30 PM Central Time

Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
10:30 AM - 12:30 PM Central Time

Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
10:30 AM - 12:30 PM Central Time

Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Abstract Poster Presenter: KURT OELKE, MD – rheumatic disease center
10:30 AM - 12:30 PM Central Time

Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Abstract Poster Presenter: Shikha Singla, MD – MCW
10:30 AM - 12:30 PM Central Time

Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
Abstract Poster Presenter: Alen Zabotti, MD, MSc – Azienda Sanitaria Universitaria del Friuli Centrale
10:30 AM - 12:30 PM Central Time

Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Abstract Poster Presenter: Alexander Garaiman, n/a – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
10:30 AM - 12:30 PM Central Time

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Abstract Poster Presenter: Mauro Keiserman, MD – Rheumatology Section, Pontifical Catholic University, School of Medicine
10:30 AM - 12:30 PM Central Time

Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Abstract Poster Presenter: Irene van der Horst-Bruinsma, MD, PhD – Radboud umc
10:30 AM - 12:30 PM Central Time

Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
10:30 AM - 12:30 PM Central Time

Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
Abstract Poster Presenter: Guillermo Gonzalez Mozo de Rosales, MD – Basurto University Hospital
10:30 AM - 12:30 PM Central Time

Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
10:30 AM - 12:30 PM Central Time

Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
10:30 AM - 12:30 PM Central Time

Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Abstract Poster Presenter: Aashish Agrawal, MD, MBBS – Hinduja Hospital
10:30 AM - 12:30 PM Central Time

Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Abstract Poster Presenter: Asim Khanfar, MD – Rochester General Hospital
10:30 AM - 12:30 PM Central Time

Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
Abstract Poster Presenter: Mark Hwang, MD,MS – UTHealth Houston
10:30 AM - 12:30 PM Central Time

Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
10:30 AM - 12:30 PM Central Time

Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
Abstract Poster Presenter: Reut Tzemach, MD (she/her/hers) – Sourasky Medical Center